1-20 of 90
Sarit Assouline
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2023) 142 (Supplement 1): 6324.
https://doi.org/10.1182/blood-2023-182434
Published: 2023
Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

L. Elizabeth Budde, Adam J Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Hao Wu, Iris To, Michael C. Wei, Julio C. Chavez
Journal: Blood
Blood (2023) 142 (Supplement 1): 613.
https://doi.org/10.1182/blood-2023-174209
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 603.
https://doi.org/10.1182/blood-2023-173692
Published: 2023
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers
Journal: Blood
Blood (2023) 142 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2023-181195
Published: 2023
Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 734.
https://doi.org/10.1182/blood-2023-174956
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 614.
https://doi.org/10.1182/blood-2023-173796
Published: 2023
Journal Articles

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Sarit Assouline, Katharine L. Lewis, Rosemary Anne Harrup, Robert J Lutz, Jenny Thirlway, Jutta Deckert, David M Browning, Debra L Wood, Paul I. Nadler, Seung Tae Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3095.
https://doi.org/10.1182/blood-2023-173955
Published: 2023
Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Clinical Trials & Observations
Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff
Journal: Blood
Blood (2023) 141 (11): 1265–1276.
https://doi.org/10.1182/blood.2022016362
Published: 2023
Includes: Supplemental data
Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline
Journal: Blood
Blood (2022) 140 (Supplement 1): 3757–3759.
https://doi.org/10.1182/blood-2022-159594
Published: 2022
Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Giovanni Zambrotta, Sarit Assouline, Franck E. Nicolini, Elisabetta Abruzzese, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez-Larran, Ana Triguero, Alessandra Iurlo, Cristina Bucelli, Francesca Lunghi, Isabella Capodanno, Margherita Maffioli, Sara Galimberti, Giovanni Caocci, Fabio Stagno, Susanne Saussele, Carmen Fava, Philipp le Coutre, Massimiliano Bonifacio, Veronica Guglielmana, Federica Colombo, Laura Antolini, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1504–1506.
https://doi.org/10.1182/blood-2022-162207
Published: 2022
Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Richard F. Little, Megan Othus, Sarit Assouline, Sherry Ansher, Ehab L. Atallah, R. Coleman Lindsley, Boris Freidlin, Steven D. Gore, Lyndsay Harris, Christopher S. Hourigan, S. Percy Ivy, Shahanawaz Jiwani, Erin Langan, Selina M. Luger, Laura C. Michaelis, Olatoyosi Odenike, David Patton, Miguel-Angel Perales, Jerald P. Radich, Bhanu Ramineni, Jesse J. Salk, Patrick Stiff, Wendy Stock, Richard M. Stone, Geoffrey L. Uy, P. Mickey Williams, Brent L. Wood, Katherine H Worthington, Laura M Yee, Amer M. Zeidan, Jianqiao Zhang, Mark R. Litzow, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9057–9060.
https://doi.org/10.1182/blood-2022-169307
Published: 2022
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Christopher K Rushton, Ryan N Rys, Elizabeth Chavez, Laura K Hilton, Miguel Alcaide, Kostiantyn Dreval, Matthew Cheung, Manuela Cruz, Krysta M. Coyle, Barbara Meissner, Susana Ben-Neriah, Neil R. Michaud, Scott Daigle, Jordan Davidson, Jasper Wong, Annette E. Hay, Michael D. Jain, Lois E. Shepherd, Marco A. Marra, John Kuruvilla, Michael Crump, Koren Kathleen Mann, Sarit Assouline, Christian Steidl, David W. Scott, Nathalie A. Johnson, Ryan D. Morin
Journal: Blood
Blood (2022) 140 (Supplement 1): 9259–9260.
https://doi.org/10.1182/blood-2022-169623
Published: 2022
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 1467–1470.
https://doi.org/10.1182/blood-2022-157691
Published: 2022
Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9464–9467.
https://doi.org/10.1182/blood-2022-157679
Published: 2022
Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Clinical Trials & Observations
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D’Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (8): 839–850.
https://doi.org/10.1182/blood.2021015014
Published: 2022
Includes: Supplemental data
Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Elizabeth Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Michelle Y. Doral, Chi-Chung Li, Huang Huang, Raluca Negricea, Elicia Penuel, Carol O'Hear, Nancy L. Bartlett
Journal: Blood
Blood (2021) 138 (Supplement 1): 127.
https://doi.org/10.1182/blood-2021-145872
Published: 2021
Journal Articles

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter, Megan Othus
Journal: Blood
Blood (2021) 138 (Supplement 1): 220.
https://doi.org/10.1182/blood-2021-151597
Published: 2021
Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2488.
https://doi.org/10.1182/blood-2021-152225
Published: 2021
Journal Articles

Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd

Olivier Del Corpo, Michael Harnois, Lambert Busque, Sarit Assouline
Journal: Blood
Blood (2021) 138 (Supplement 1): 4602.
https://doi.org/10.1182/blood-2021-151761
Published: 2021